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Results. 76 patients were assessed (age: 60.9±10.9 years old; men: 53.9%; outpatients: 65.8%). Most frequent tumors: lung (21.1%),
colon/rectum (14.5%) and breast (13.2%). 61.8% received transdermal fentanyl 25g, and presented a mean pain intensity of
5.3±2.2 on the week before inclusion. 64.4% suffered 2–3 BTcP episodes/day [average duration per episode, 10–30’: 49%, and >30’:
47%. Time to maximum intensity, 10–30’: 39% and >30’: 5.8%]. Titration period was started by 75.4% of patients, being 100–400g
the most common effective doses (87.9%). Quality of life and functional status improved comparing to previous medication in
all 7 items of the Brief Pain Questionnaire (BPI), as well as global patient satisfaction with treatment, highlighting its ease of use
by 100% of patients.
Conclusions. Preliminary results in Spain show that effective dose of FBT after titration gets established between 100 and 400g,
improving QoL and functional status of cancer patients who suffer BTP, as well as their global satisfaction with treatment. For
now, it is not possible to predict what patients will respond better to 100g or 200g doses.
http://dx.doi.org/10.1016/j.rpor.2013.03.838
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Objectives. Evaluate the efﬁcacy of glutamine in the prevention of the incidence of oral mucositis secondary to cancer therapies
in patients with HNC. Secondary objectives were to know the incidence of odynophagia, interruptions of treatment, the dose of
radiation at the time of the secondary effects and the requirements of analgesia and nasogastric tube.
Material and Methods. Prospective cohort study of patients with squamous cell carcinoma of HNC treated with radiother-
apy± concomitant chemotherapy. We compared 131 patients receiving glutamine orally at a dose of 10mg/8h from 7 days
before the start of radiotherapy until the end of the treatment with 131 patients who did not receive it.
Results. Patients not taking glutamine had a hazard ratio 1.78 times higher of mucositis, 95% CI (1.01–3.16), p=0.047. Regarding
odynophagia patients not taking glutamine had a hazard ratio 2.87 times higher, 95% CI (1.62–5.18), p = 0.0003. The 19.8% of
patients who did not take glutamine discontinued treatment versus 6.9% of patients who took, p=0.002. The mean dose of
radiation at the time of occurrence of mucositis and odynophagia was 30.9 Gy and 29.8 Gy respectively in patients without
glutamine versus 43.5 Gy and 40.1 Gy in patients with glutamine, both p<0.001. Regarding support requirements 87.8% of patients
without glutamine required analgesia versus 77.9% of patients with glutamine, p=0.03 and nasogastric tube was indicated in
9.9% and 3.1% respectively, p=0.02.
Conclusion. Oral glutamine in patients receiving cancer treatments for HNC, prevents the incidence of oral mucositis and
odynophagia, delays the onset of these toxicities, decreases treatment interruptions and the use of analgesia and nasogastric
tube.
http://dx.doi.org/10.1016/j.rpor.2013.03.839
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Introduction. Sleep and anxiety difﬁculties are concerns of breast cancer patients. Knowledge of the nature and prevalence of
these problems can provide the basis for new approaches to supportive care because many sleep problems and anxiety can be
treated.
Objectives. To determine sleep problem and anxiety prevalences in breast cancer patients who attended for the ﬁrst time to a
Radiation Oncology Department. To establish the nature of sleep disturbances and its associations with patient’s characteristics,
treatments, and psychological symptoms.
Patients and methods. This cross-sectional survey study examined 48 breast cancer patients between October 2010 and March
2012. All patients were offered two brief sleep and anxiety screening tools (COS and HARS, respectively). Our patients’ charac-
teristics were: Mean age 56.13 years (range=37–78); Clinical Stage: I (58.3%); II (29.2%); III (6.3%); and IV (6.3%); and KPS: 99.17
(range=70–100).
Results. Our patients were satisﬁed with their sleep process (M=4.37; range=3–7). When insomnia was present, it was mild or
moderate in the 75% of cases. Main insomnia problems were: difﬁculty to fall asleep (33.3%); waking up several times (18.8%);
waking up too early (8.3%); daytime sleepiness related to insomnia (31.3%). Insomnia treatments were: Benzodiazepines (41.7%);
herbal medicines (8.3%); Our series showed a global anxiety mean score of 14.17 (minor anxiety). Signiﬁcant associations (p< .05)
were found between greater insomnia levels and a) younger patients (r=−.30); and b) higher anxiety scores (r= .57). An insomnia
explanatory model was found for the global anxiety score (R2c= .27). Sleep satisfaction was associated with global anxiety score
(r=−.60; p< .05). Sleep satisfaction was only predicted by psychological anxiety component (R2c= .31).
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Conclusions. We recommend the use of sleep and anxiety screening tools in breast cancer patients, which provide relevant
information in planning supportive care services.
http://dx.doi.org/10.1016/j.rpor.2013.03.840
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Introduction. Concomitant preoperative radiotherapy with capecitabine is one of the choice treatments in patients with rectal
adenocarcinoma. This treatment has beneﬁts for local tumor control, however it does have its complications affecting quality
of life. Change in diet is essential as prophylaxis in this case. The aim of this paper is to prove the superiority of a steady diet
versus general recommendations in regards to reducing the frequency and severity of diarrhea.
Material and methods. A prospective, randomized, controlled trial of 29 patients. Patients were divided into two groups: control
group, patients on recommendations based on exclusion diets and a steady diet group. Patients were evaluated at baseline, at
three weeks and after radiotherapy. At each visit we evaluated the weight, toxicity (CTC v2.0 scale) and quality of life with the
validated FACIT-D questionnaire.
Results. The median dose was 45Gy. Fourteen patients were included in the control group and 15 in the steady diet group. The
control group showed a signiﬁcant increase in incidence and grade of acute diarrhea (≥G2) at the end of treatment compared
with the steady diet group (p=0.035). The mean weight loss in the control group at 3 weeks was 1.02kg while there was a 1.22kg
(p=0.024) gain in the steady group. At the end of the treatment, the control group lost 2.12 kg and the steady diet group gained
1.41kg (p=0.001). At three weeks, patients in steady group showed less decreased in quality of life than control group (p=0.02).
These differences remained at the end of the radiotherapy, although it was not signiﬁcant (p=0.64).
Conclusions. The steady diet reduces the incidence of acute radiation diarrhea compared to that of general recommendations.
Moreover, this diet reduces weight loss signiﬁcantly and could reduce the impact of quality of life.
http://dx.doi.org/10.1016/j.rpor.2013.03.841
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Introduction. Cervical ﬁbrosis is a prevalent and symptomatic side effect in patients receiving radiotherapy for head and neck
cancer. The association pentoxifylline-tocopherol is the only treatment that has proven effectiveness so far. Hyperbaric oxygen
therapy is effective for some complications of radiation and may increase the pharmacological effect through its angiogenic
capability.
Objetives. To assess if the addition of hyperbaric oxygen therapy, improves the results of pentoxifylline and tocopherol for
radiation-induced ﬁbrosis in patients treated for head and neck cancer.
Methods.Anopen, controlled, randomized clinical trialwasperformedwith irradiatedpatients andat leastGrade II cervical ﬁbrosis
in LENT-SOMA scale. Arm 1: pentoxifylline 400mg b.i.d and tocopherol 400 mg b.i.d for six months. Arm 2: same pharmacological
treatment and 25 sessions of hyperbaric oxygen between 3rd and 9th week. These sessions were administrated in a multiplace
chamber with 100% oxygen at 2,4 ATA for 90min, ﬁve times a week. Clinical evaluation was performed at zero, three and six
months.
Results. Thirty-seven patients were randomized and 26 completed the trial, 13 in every arm. Treatment was well tolerated and
only two patients suspended by drug intolerance. Patients that improved their ﬁbrosis in at least one grade were: – Arm 1(only
drugs): 1/13 at 3 months and 4/13 at 6 months – Arm 2(drugs and hyperbaric oxygen): 6/13 at 3 months and 10/13 at 6 months
Differences between arms were statistically signiﬁcant (p=0.001 at 3 months and p=0.047 at 6 months).
Conclusions. The addition of hyperbaric oxygen therapy signiﬁcantly improves the results of drug therapy in cervical subcutaneous
ﬁbrosis at three and six months. The efﬁcacy of the combination of these treatments had never been published.
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